ALTERNATING USE OF DIFFERENT JAK1/JAK2 INHIBITORS, A POSSIBLE THERAPEUTIC STRATEGY USEFUL IN PRIMARY MYELOFIBROSIS: A CASE REPORT

被引：0
|
作者：
Gutierrez, Lopez de Ocariz X. [1 ]
Vera, Guerrero E. [1 ]
Carreno, Gomez-Tarragona G. [1 ]
Buendia, Urena B. [1 ]
De Nicolas, Sol R. [1 ]
Hidalgo, Soto M. [1 ]
Lopez, Munoz N. [1 ]
Zamanillo, Herreros, I [1 ]
Iniguez, Garcia R. [1 ]
Poza, Santaella M. [1 ]
Ayala, Diaz R. [1 ]
Martinez, Lopez J. [1 ]
机构：
[1] Hosp Univ 12 Octubre, Madrid, Spain
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB-059
引用
收藏
页码：395 / 395
页数：1
相关论文
共 50 条
  • [21] Case report: Refractory Evans syndrome in two patients with spondyloenchondrodysplasia with immune dysregulation treated successfully with JAK1/JAK2 inhibition
    Gernez, Yael
    Narula, Mansi
    Cepika, Alma-Martina
    Camacho, Juanita Valdes
    Hoyte, Elisabeth G.
    Mouradian, Kirsten
    Glader, Bertil
    Singh, Deepika
    Sathi, Bindu
    Rao, Latha
    Tolin, Ana L.
    Weinberg, Kenneth I.
    Lewis, David B.
    Bacchetta, Rosa
    Weinacht, Katja G.
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [22] Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3
    Malerich, Jeremiah P.
    Lam, Jennifer S.
    Hart, Barry
    Fine, Richard M.
    Klebansky, Boris
    Tanga, Mary J.
    D'Andrea, Annalisa
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (24) : 7454 - 7457
  • [23] Evaluating the Serial Use of the Myelofibrosis Symptom Assessment Form for Measuring Symptomatic Improvement Performance in 87 Myelofibrosis Patients on a JAK1 and JAK2 Inhibitor (INCB018424) Clinical Trial
    Mesa, Ruben A.
    Kantarjian, Hagop
    Tefferi, Ayalew
    Dueck, Amylou
    Levy, Richard
    Vaddi, Kris
    Erickson-Viitanen, Susan
    Thomas, Deborah A.
    Cortes, Jorge
    Borthakur, Gautam
    Pardanani, Animesh D.
    Estrov, Zeev
    Verstovsek, Srdan
    CANCER, 2011, 117 (21) : 4869 - 4877
  • [24] The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3
    Lee, Sun-Mi
    Yoon, Kyoung Bin
    Lee, Hyo Jeong
    Kim, Jiwon
    Chung, You Kyoung
    Cho, Won-Jea
    Mukai, Chisato
    Choi, Sun
    Kang, Keon Wook
    Han, Sun-Young
    Ko, Hyojin
    Kim, Yong-Chul
    BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (21) : 5036 - 5046
  • [25] 2,5-Isomers of triazole-pyrrolopyrimidine act as selective inhibitors of Janus kinase 2 (JAK2) compared to JAK1 and JAK3
    Sun-mi, Lee
    Kim, Yong-Chul
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [26] Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis
    P Guglielmelli
    F Biamonte
    A Spolverini
    L Pieri
    A Isgrò
    E Antonioli
    A Pancrazzi
    A Bosi
    G Barosi
    A M Vannucchi
    Leukemia, 2010, 24 : 1533 - 1537
  • [27] Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis
    Guglielmelli, P.
    Biamonte, F.
    Spolverini, A.
    Pieri, L.
    Isgro, A.
    Antonioli, E.
    Pancrazzi, A.
    Bosi, A.
    Barosi, G.
    Vannucchi, A. M.
    LEUKEMIA, 2010, 24 (08) : 1533 - 1537
  • [28] Use of the JAK2 inhibitor ruxolitinib in myelofibrosis relapsing post allogeneic stem cell transplant: case report
    Publicover, A.
    Ganczakowski, M.
    Duncombe, A.
    Hill, K.
    Hurlock, C.
    Jenner, M.
    Main, S.
    McKeag, N.
    Newman, J.
    Richardson, D. S.
    Orchard, K. H.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 62 - 62
  • [29] Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2
    Zak, Mark
    Mendonca, Rohan
    Balazs, Mercedesz
    Barrett, Kathy
    Bergeron, Philippe
    Blair, Wade S.
    Chang, Christine
    Deshmukh, Gauri
    DeVoss, Jason
    Dragovich, Peter S.
    Eigenbrot, Charles
    Ghilardi, Nico
    Gibbons, Paul
    Gradl, Stefan
    Hamman, Chris
    Hanan, Emily J.
    Harstad, Eric
    Hewitt, Peter R.
    Hurley, Christopher A.
    Jin, Tian
    Johnson, Adam
    Johnson, Tony
    Kenny, Jane R.
    Koehler, Michael F. T.
    Kohli, Pawan Bir
    Kulagowski, Janusz J.
    Labadie, Sharada
    Liao, Jiangpeng
    Liimatta, Marya
    Lin, Zhonghua
    Lupardus, Patrick J.
    Maxey, Robert J.
    Murray, Jeremy M.
    Pulk, Rebecca
    Rodriguez, Madeleine
    Savage, Scott
    Shia, Steven
    Steffek, Micah
    Ubhayakar, Savita
    Ultsch, Mark
    van Abbema, Anne
    Ward, Stuart I.
    Xiao, Ling
    Xiao, Yisong
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (13) : 6176 - 6193
  • [30] JAK1/2 Inhibition in Severe TAFRO Syndrome: A Case Report
    Killian, Martin
    Viel, Sebastien
    Chalayer, Emilie
    Forest, Fabien
    Grange, Sylvain
    Bonnefoy, Pierre-Benoit
    Oksenhendler, Eric
    Cathebras, Pascal
    Paul, Stephane
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (05) : 719 - +
12345